Stelerix Web Blog Knowledge at your Fingertips

29Mar/110

Pharma Pricing Video Analysis

If you are looking for cutting edge knowledge at your fingertips, with regards to Pharma Pricing. You should definitely check out the recent pricing analysis video I did for Nexavar. It's only a few minutes long but I really show what happens in the immediate quarters following Nexavar approval for hepatocellular carcinoma.

You can read more about pharma pricing strategy and market access here.

Posted by Jeff

28Feb/110

Green in Action

In light of our upcoming renewable energy webinar series, we are always looking for compelling content that encourages our case for action.

Please check out the Renewable Energy Information Portal this morning, as we've made some updates that further highlight proactive policy within Canada, and underscore the need for a sustainable push forward.

Posted by Jeff

15Feb/110

KOL Engagement and Alignment.

Here's a quick excerpt from our Special Comprehensive Country Report, India. It's something we've seen addressed again and again in our follow-up interviews.  I've also thrown in a YouTube interview with Tushar Barad who talks about some of the intricacies of engaging with KOLs.

The updated report will be exclusively available for free through our great friends over at pharmaphorum. So you better get registered!

"Respondents identified active engagement of local Key Opinion Leaders as the most effective means to understand their needs. Further, this strategy provides accurate insight into actual affordability as demonstrated by purchasing power and cost of living, in addition to possible commercial strategies and their respective likelihoods. However, our research also suggested that organizations as a whole have been slow to actively engage end-users. Patience and value on the long term was also a key trend among respondents. It was evident from our results that success in India favors ongoing and long-term relationships that grow and evolve over time. While short-term profit can be made, it is clear that the initial time investment and requisite patience were rewarded many times over when focus was placed on the longer term.  A further benefit of continuous investment in “relationship capital” is the evolution of mutually business partnerships. Organizations who establish themselves effectively in India can often leverage their presence to reach other fast-growing markets in the South-Asian and Asia-Pacific region. Our experts agree that to be effective into 2020 and beyond, market leaders must invest proactively in nascent relationships, given the propensity for longer cycle time in such business partnerships. Opportunity to cut costs and drive access will exist for those who look to partner and aid, rather than exploit."

Posted by Jeff

Oh yeah, the full report will also be available for download here, but this week only!!

1Feb/110

Common Hurdles.

Here in Canada, we often hear about a potentially-crippling void of innovation. Closer inspection indicates that it isn't for lack of research. In fact, it's a sub-par commercialization process that is culpable for the dropped ball.

This is of course a common theme, but I was surprised to hear it mentioned to me by Kiran Mazumdar Shaw, the Managing Director of India's largest biotechnology company, Biocon. "Scientist entrepreneurs are few and far between - what challenges our scientists in advancing their research into businesses?"

And as all our research is guided by primary interactions with stakeholders, so this will be the guiding question, over the course of the next few interviews. Stay tuned for step-by-step examples of entrepreneurs who have commercialized their developments.

24Jan/110

Greenovations.

We focus on a few specific verticals. We bridge global knowledge gaps and connect people with the cutting edge knowledge and technology they need.

One of such verticals is Renewable Energy. We have partnered with Canadian GreenTech, a premium provider of high quality renewable energy news, to collaborate on a series of renewable energy webinars.

We have been lucky enough to source some premium cutting-edge articles from Canadian GreenTech, the most recent of which is hosted here.

You can also check out the exciting webinar series here.

Posted by Jeff

18Jan/110

Call for Questions.

We have an interview upcoming with Vivek Shukla, later next week.

His 12  years of experience serving over 40 reputable clients in the Indian pharmaceutical industry have given him a grasp of strategic business knowledge that is unrivaled.

Now is your chance to pick the brains of a world-class expert. Comment or send questions to info@stelerix.com

Posted by Jeff

13Jan/110

Call for Questions!

I have a number of interviews coming up.  I am really excited to have the opportunity to speak to experienced stakeholders. It is bound to be one engaging and informing discussion after another.

Get ready for a flood of quality content in the latter half of next week.

I have done my best to think up intriguing questions. They are all based on direct input from our preliminary research and direct industry stakeholder input, like this. But I'm still new to the interview game. So if you have ideas or are burning for answers, please send them to us!

If you could pick the brain of an emerging market expert, what would you ask?

If you need some inspiration, here are some tried and true questions (and answers).

Alok Kumar, Part 1, Part 2 (FREE On-Demand webinar)

Vivek Varma - Contract Manufacturing

Posted by Jeff

12Jan/110

Exclusive Interview, Part 2

I woke up at 3:30am (2:00pm IST) the other day, to find out about lessons learned  in competitive generic global product launches.

The follow-up to our first exclusive interview is now online.

Watch this FREE, on-demand webinar to understand:

  • What the Indian market will look like in ten years
  • What differentiates it from
  • Strategies for generics success.
  • How to deal with regulatory hurdles and surprises.

It's our first attempt at supplementing an audio call with powerpoint presentations and a full minute-by-minute note-guide. We are very eager to improve and should have a version with improved sound quality up by tomorrow. Your comments and thoughts are encouraged.

FREE On-Demand Webinar - Alok Kumar discusses what is required for generics success in India, and the world.

Posted by Jeff

11Jan/110

Local Savvy

Here's an excerpt from our recent premium research:

"Of course, respondents identified active engagement of local people as the most effective means to understand their respective needs, as well as what they are able to pay to address them. However, our research also suggested that organizations as a whole have been slow to engage end-users actively. Patience and value on the long term was also a key trend among respondents. It was evident from our results that success in India favors ongoing and long-term relationships that grow and evolve over time. It is clear that the initial time investment and requisite patience were rewarded many times over in the longer term"

It's interesting, given some recent developments in the news.

Despite minor analytical shortcomings, the researchers identified different factors influencing prescription in a number of regions. It's evident that local stakeholder engagement is critical as our research said.

Alternatively, big pharma can continue to acquire leading domestic players. Abbott complemented it's own internal efforts by buying up Piramal. It plans to let the business operate independently with current management; a robust strategy, judging by our research.

We touch more on the subject of how to successfully partner with local influences and key opinion leaders in our follow-up interview with Alok Kumar (original here). It will be an audio presentation supplemented with powerpoint slides, available soon!

Sign up for our newsletter to be kept up to date!

Posted by Jeff

10Jan/110

Shlomo Maital: India’s Secret Weapon.

"Would you tell me, please, which way I ought to go from here?"
"That depends a good deal on where you want to get to," said the Cat.
"I don’t much care where--" said Alice.
"Then it doesn’t matter which way you go," said the Cat.

"--so long as I get SOMEWHERE," Alice added as an explanation.
"Oh, you’re sure to do that," said the Cat, "if you only walk long enough."
Lewis Carroll, Alice in Wonderland.

I first became aware of Shlomo's work after falling in love with his insightful piece: India's Secret Weapon.

If you have not read this short essay, you would be remiss to close this page without perusing the referenced link.

It confirms my own ideas about the value of education. It also provides vivid insight into the scope and scale of education in India. It has obviously and intelligently been made a national and cultural priority. Even without Shlomo's incredibly compelling endorsement, it easy to begin to understand the potential of such large-scale initiatives. And it is exciting to imagine what it all might mean for the world at large.

In his new book, Global Risk/Global Opportunity, Shlomo Maital offers ten tools to help managers evaluate risk and exploit global opportunity by observing minds, markets and money. This is especially important today, given the increasingly connected global world. Because while we strive for an integrated and connected globe, thinking globally is harder than most imagine. To truly wrap your mind around the problem and understand the factors at play is a challenge. Eye-witness accounts and an eagerness and openness to understand and learn are a great starting point.

But in starting out, you must know where you want to end up. To this end, once again, Shlomo Maital provides valuable and intellectually stimulating insight:

Posted by Jeff

Page 1 of 41234